Search
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings … Calcium glycerophosphate is a [DB01373] salt of glycerophosphoric acid that forms a white, fine, slightly hygroscopic powder.
Mixtures: Alsimine W Vitamins A DDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalbinding at the ATP domain of the epidermal growth factor receptor family kinase domains. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexAntrafenine
go.drugbank.com/drugs/DB01419ApprovedIt is not widely used as it has largely been replaced by newer drugs. … Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigationalextensively investigated as an immunosuppressive and antitumour agent. … [A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexGolimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationaltreatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalThe FDA said it is keeping the black box in place at least until the results of the trial are announced. … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S.
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug to recruit CD3-expressing T cells to BCMA-expressing … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerMetaraminol
go.drugbank.com/drugs/DB00610ApprovedAn adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. … It has been used primarily as a vasoconstrictor in the treatment of hypotension.
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.